Abstract. The carboxy-terminal region of dystrophin has been suggested to be crucially important for its function to prevent muscle degeneration. We have previously shown that this region is the locus that interacts with the sarcolemmal glycoprotein complex, which mediates membrane anchoring of dystrophin, as well as with the cytoplasmic peripheral membrane protein, A0 and/
the amino acid residues encoded by exons 73-74 which are alternatively spliced out in some isoforms. This suggests that the function of syntrophin is tightly linked to the functional diversity among dystrophin isoforms. Pathologically, it is important that the binding site for od-syntrophin, which is predominantly expressed in skeletal muscle, coincides with the region whose deletion was suggested to result in a severe phenotype. In addition, A0, a minor component of dystrophin-associated proteins with a molecular mass of 94 kD which is immunochemically related to syntrophin, binds to the same site as ~-syntrophin.
Finally, based on our accumulated evidence, we propose a revised model of the domain organization of dystrophin from the view point of protein-protein interactions.
VSTROPHIN, the protein product of the Duchenne muscular dystrophy (DMD) ~ gene, is a spectrinlike, long slender protein with a molecular mass of 427 kD CKoenig et al., 1987 CKoenig et al., , 1988 Hoffman and Kunkel, 1989) . Immunohistochemicai and biochemical studies have revealed that it is located on the cytoplasmic surface of the sarcolemma and works as a major component of subsarcolemmal cytoskeleton (Watkins et al., 1988; Arahata et al., 1988; Ohlendieck et al., 1991) . Although the defect of this protein has been shown to cause DMD, the molecular mechanism underlying this muscle degeneration process is not well understood yet.
We have focused our attention to the COOH-terminal region of dystrophin, because this region has been suggested to be pathologically important (Beggs et al., 1991) . Our previous work has proven that this region is involved in interactions with a number of dystrophin-associated proteins (DAPs), including the components of the sarcolemmal glycoprotein complex (GPC) which mediates membrane anchoring of dystrophin (Yoshida and Ozawa, 1990; Suzuki et al., 1992 Suzuki et al., , 1994 . GPC is composed of at least four membrane-spanning glycoproteins (adhalin [50DAG], 13-dystroglycan [43DAG], A3b and 35DAG) and one extracellular proteoglycan (c~-dystroglycan [156DAG]) (Ervasti et al., 1990; Yoshida and Ozawa, 1990; Ervasti and Campbell, 1991; Ibraghimov-Beskrovnaya et al., 1992 Roberds et al., 1993) . The GPC-binding site on dystrophin is located in a widely extended region encompassing the cysteine-rich domain and the first half of the COOH-terminal domain , the deletion of which had been shown to obligatorily lead to severe phenotypes (Beggs et al., 1991) . Therefore, the lack of interaction between this COOH-terminal region and GPC was suggested to be one of the essential causes of the disease. On the other hand, among the components of GPC, the protein which directly interacts with this GPC-binding site is B-dystroglycan . From our recent studies which showed that/~-dystroglycan extracellularly binds to the laminin-binding ct-dystroglycan and forms a distinctive subcomplex in GPC named dystroglycan complex, we suggest that the interaction between dystrophin and the dystroglycan complex may serve an essential link between dystrophin and the extracellular matrix (Ibraghimov-Beskrovnaya et al., 1992; Ervasti and Campbell, 1993; Suzuki et al., 1994; Yoshida et al., 1994) .
The NH2-terminal domain of dystrophin has been shown to bind actin filaments in vitro (Way et al., 1992; Ervasti and Campbell, 1993) . Therefore, it has been postulated that dystrophin mediates the linkage between the extracellular matrix and the actin-based subsarcolemmal cytoskeleton, and the disruption of this linkage results in the damage of the sarcolemma, which, in turn, leads to muscular degeneration (Ervasti and Campbell, 1993; Ohlendieck et al., 1993) . However, recent results indicated that, even in the presence of this linkage, muscles may degenerate (Matsumura et al., 1992; Yamanouchi et al., 1994; Mizuno et al., 1994) : in the skeletal muscle of the other type of muscular dystrophy (severe childhood autosomal recessive muscular dystrophy [SCARMD] ) and its animal model, dystrophin and the dystroglycan complex are expressed almost normally and show normal membrane localization, whereas other components of GPC, namely adhalin, 35DAG and A3b, which form the other subcomplex in GPC named sarcoglycan complex , are selectively reduced. Therefore, it is beginning to appear that, as a complicated protein complex constituted by the dystroglycan and sarcoglycan subcomplexes, GPC not only serves a membrane-anchoring site for dystrophin, but also exerts a more sophisticated function which is crucial for muscle fiber maintenance. In this sense, the COOH-terminal region of dystrophin becomes more important as a locus where complicated protein-protein interactions may occur (Bowe et al., 1994) .
In addition to the sarcolemmal glycoproteins in GPC, the cytosolic peripheral membrane proteins, A0 and ot-/fl-A1 (59DAP), have been reported to be copurified with rabbit skeletal muscle dystrophin (Ervasti et al., 1990; Yoshida and Ozawa, 1990; Ervasti and Campbell, 1991) . Among them, or-and fl-A1 were recently shown to be the mammalian homologues of a Torpedo 58-kD postsynaptic protein, syntrophin, which has been suggested to be involved in clustering acetylcholine receptors (Froehner 1984 (Froehner , 1987 Adams et al., 1993; Alan et al., 1994; Yang et al., 1994) . In agreement with other laboratories, we renamed a-and fl-A1 as t~l-and fll-syntrophin, respectively (Peters et al., 1994) . In the previous paper, we have shown that A0 and fll-syntrophin also bind to the dystrophin COOH-terminal region directly, and their binding sites are located within the distal half of the COOH-terminal domain . In the present paper, we advanced the analysis on the binding site for fll-syntrophin and A0 by using the overlay assay method we developed previously . In the course of this study, we found that not only fll-syntrophin but also od-syntrophin (syntrophin-1, 59DAP-I), binds directly to dystrophin. The defined binding sites for the two syntrophin isoforms are located very close to each other on the dystroplain molecule but are made up of completely different amino acid sequences. Interestingly, both binding sites are confined within the region which is alternatively spliced out depending on tissue types (Feener et al., 1989; Bies et al., 1992) . The results we obtained here may provide important clues for the biological function of syntrophins.
Materials and Methods

Expression and Purification of Dystrophin Deletion Mutants as Fusion Proteins with Glutathione-S-Transferase
All deletion mutant constructs shown in Fig. 1 were generated from pGEX/DCT685 described previously using restriction enzymes. This construct contained the 3.7-kb HindIII fragment of dystrophin encoding the COOH-terminal residues 3026-3685, which we ligeted into the EcoRI site of pGEX-3X (Pharmacia LKB Biotechnology, Piscataway, NJ) using HindIII-EcoRI adapters made by mixing EcoRI-SmaI and HindIII-EcoRI adapters (Takara Shuzo Co., Ltd., Kyoto, Japan). During the construction of deletion mutants, the correct colonies were verified by restriction mapping of the recombinant plasmids or immunoscreening with region-specific anti-dystrophin antibodies (see Fig. 1) .
A COOH-terminal deletion mutant, pGEX/DCT535, was constructed by a cut of the pGEX/DCT685 at a convenient XbaI site within the 3' untranslated region (UTR) and at a StuI site, followed by end blunting and religation. For construction of pGEX/DCT263-685 and pGEX/DCT536-685, a 3.2-kb BamHI-EcoRI fragment of pGEX/DCT685 was at first subcloned into pGEX-2T to adjust the reading frame: pGEX/DCT685 was digested with BamHI and EcoRI and the 3.2-kb restriction fragment derived from the insert was purified from an agaroso gel and religated into complementary sites in pGEX-2T. The resultant plasmid was digested by BamI-II/AccIlI for pGEX/DCT264-685 or by BamHI-StuI for pGEX/DCT536-685 and religated after end blunting, pGEX/DCT444-685 was constructed by the use of a NheI site within the COOH-terminal coding sequence. To achieve this, the NheI site in the 3' untranslated region was first deleted as follows. pGEX/DCT685 was digested with BamHl and religated to remove nucleotides containing the EcoRI site in the 5' polylinker site (PLS). The cloned plasmid, which was named pGEX/DCT194-685, was then cut at an XbaI site in the 3' untranslated region, and at an EcoRI site in the 3' polylinker site to remove nucleotides containing the second NheI site. After the resultant plasmid was blunt ended, religeted, and cloned, the construct pOEX/ DCT444-685 was generated by a cut of the plasmid with Baml~-NheI and religeted after end blunting. To generate pGEX/DCT444-535 and pGEX/ DCT444-494, pGEX/DCTI94-685 was digested with StuI-SmaI and Bglll-SmaI, respectively, blunt ended and religated. This procedure removed the second NheI site in the 3' untranslated region. Each cloned plasmid was then processed by BamI-II-NheI digestion, blunt ended, and religated.
Expression and Purification of the Fusion Proteins
Recombinant proteins were expressed in E. coli and purified from the soluble fraction of cell lysates with the glutathione-Sepharose column essentially as described previously . The Ion-mutant (ME8426) of E. coil was also used as a host strain for the expression of DCT685, DCT535, DCT442, DCT264, and DCT264-685, since these were very susceptible to bacterially endogeneous proteases. To remove degradation products with low molecular masses, gel filtration was performed for these constructs on Superose 12 (Pharmacia LKB Biotechnology). For the other fusion proteins which were stably expressed, the strain HB101 was used and the gel-filtration procedure was omitted. As we described previously , the original method (Smith and Johnson, 1988) of purifying the GST-fusion proteins was modified by the addition of a washing procedure of the glutathione-Sepharose resin-adsorbed fusion proteins with PBS (150 mM NaC1, 10 mM NaH2PO4/NaOH, pH 7.5) containing 3 mM Mg-ATP, 1 mM DTT and proteinase inhibitors (2 #g/ml leupeptin, 0.5 #g/nil aprotinin, 1 mM benzamidine and 0.1 mM PMSF). This procedure eliminates contaminating E. coil DnaK (the analog of the vertebrate heatshock protein 70). In the case of DCT264-685 purification, this washing buffer was changed to a caseirdMg-ATP buffer (30 mM Tris/HCI, 50 mM KCI, 5 mg/ml casein, 10 mM MgCI2, 10 mM ATE 2 mM DTT and inhibitors, pH 7.5), and the washing period was prolonged to more than 20 rain at room temperature, because the sample contained E. coil GroEL (the analog of the vertebrate heat-shock protein 60) in addition to DnaK.
Overlay-binding Assay
The overlay-binding assay was also performed as previously described . Briefly, dystrophin-DAP complex (l #g) purified from rabbit skeletal muscle (Yoshida and Ozawa, 1990; Suzuki et al., 1992) was electrophoretically separated on a 10% gel by SDS-PAGE and transferred onto a polyvinylidene difluoride membrane. After being blocked with the PBS containing 0.1% casein and 0.1% gelatin overnight at 4"C, the membrane was incubated with purified fusion proteins for 2 h at room temperature in the presence of 1 mM DTT. Bound fusion proteins were detected with anti-dystrophin antibodies.
• Electrophoresis and Immunostaining Analysis
For overlay assay, SDS-PAGE and protein transfer to a polyvinylidene difluoride membrane were performed as described (Laemmli, 1970; KyhseAnderson, 1984) . For characterization of the expressed fusion proteins, we used an automated electrophoresis system, Phast System (Pharmacia LKB Biotechnology), using the 12.5 % precast mini-gel PhastGel for convenience and saving samples. Two-dimensional PAGE was performed essentially according to the method of O'Farrell as described previously (O'Farrell, 1975; Yamamoto et al., 1993) . Briefly, 1 /~g of dystrophin-DAP complex denatured with 8 M urea and 2% ~-mercaptcethanol was isoelectrophoretically separated on 1% polyacrylamide capillary gel (4 cm × 1 mm i.d.) containing 8 M urea, 0.5% NP-40 and 2% Ampholine pH 3.5-10. After being equilibrated with a solution containing 0.15 M Tris/HCl (pH 6.8), 2% SDS, 5 % B-mercaptoethanol and 10 % glycerol, the capillary gel was placed laterally on top of a 10% slab gel and subjected to SDS-PAGE. Immunostaining was carried out by the use of the Vectastain ABC kit (Vector Labs., Inc., Burlingame, CA) for fusion protein characterization or the Elite ABC kit for overlay assay.
Antibodies
The region-specific anti-dystrophin antibodies used in this study were as follows. The polyclonal antibodies P31b, P33c, and P34a, which were previously reported (Tanaka et al., 1989; Suzuki et al., 1992) , were raised against the synthetic polypeptides corresponding to the amino acid sequences of human dystrophin 3186-3200, 3373-3391, and 3495-3544, respectively. A new polyclonal antibody, PEX73, was generated in Japanese white rabbits with GST-free DCT444-494 as an antigen. The antigen was prepared by digestion of DCT444-494 with thrombin and purified by SDS-PAGE on a 20% gel followed by a cut of the corresponding band. A monoclonal antibody, Dy8/6C5, which was raised against the synthetic polypeptide corresponding to the last 17 amino acids at the COOH terminus of the human dystrophin was purchased from Novocastra Laboratories, Ltd. (NE2, 4AA, UK) Peptides P34 peptide, which corresponds to the amino acid residues 3495-3544 of the human dystrophin sequence, was the same as the one used for preparation of the region-specific anti-dystrophin antibody P34a (Tanaka et al., 1989) .
Results
Expression and Purification of Dystrophin Mutants
In our previous work, we constructed a dystrophin fusion protein, DCT685 (Fig. 1) , which expresses the dystrophin COOH-terminal amino acid residues corresponding to the cysteine-rich domain and the entire COOH-terminal domain, and found that it specifically binds to three DAPs, ~dystroglycan (43DAG), A0, and fll-syntrophin see Fig. 3 lane 3) . In that work, by using the two COOH-terminal deletion mutants of DCT685, DCT442, and DCT264, we mainly studied the interaction between the GPC-binding site and/3-dystroglycan. In the present work, to focus on the interactions of dystrophin C O O H terminus with A0 and/31-syntrophin and confine their binding site(s), we newly constructed three kinds of NH2-terminal deletion mutants of DCT685, namely, DCT264-685, DCT444-685, and DCT536-685, as well as one additional COOH-terminal deletion mutant, DCT535 (Fig. 1) . In Fig. 2 a the typical SDS-PAGE pattern of each fusion protein sample used for the following assays is shown. All of them were confirmed to be reasonably recognized by the predictable regionspecific anti-dystrophin antibodies shown in Fig. 1 (data not shown).
Binding Site(s) for AO and [31-Syntrophin Reside within Residues 3444-3535
Dystrophin fusion proteins were examined for the DAPbinding activity by the blot overlay assay (Fig. 3) . As we Figure 1 . A Schematic diagram of dystrophin deletion mutants fused to glutathione-S-transferase (GST). The largest bar is a schematic representation oftbe dystrophin COOH terminus showing the domain organization predicted by Kunkel and co-workers (Koenig et al., 1988; Hoffman and Kunkel, 1989) . The restriction endonuclease sites used to construct truncated dystrophin expression vector and the amino acid scale are illustrated above the dystrophin diagram. Vertical lines below the diagram show the position of the cysteine residues. Some of the reported alternative splicing patterns of exons 71-74 are also indicated (Feener et al., 1989; Bies et al., 1992) . Shaded bars indicate the locations of GPC-and syntrophin-binding sites defined in the previous ) and the present studies, respectively. A set of smaller bars below shows the locations of the constructed fusion proteins and a synthetic peptide, P34 peptide. The locations of the epitopes for the region-specific anti-dystrophin antibodies used in this study are shown by black bars. The results of the overlay assay method presented here are summarized on the right of each fusion protein. Figure 3 . The inclusive results of the overlay assays using the constructed dystrophin-deletion mutants. Dystrophin-DAP complex (1 /xg) was separated on a 10% gel by SDS-PAGE and transferred onto a polyvinylidene difluoride membrane. Blot overlay was carried out as described previously . The fusion proteins used are indicated at the top of the lanes, except for CBB, which means a Coomasie blue-stained blot which is not processed by overlay (lane 1 showed previously , the binding of dystrophin COOH terminus to A0 and /31-syntrophin is disrupted if the residues downstream from 3443 are deleted (lanes 5 and 6). On the other hand, a newly constructed COOH-terminal deletion mutant, DCT535 retains the binding ability to both At) and/31-syntrophin, suggesting that the amino acid residues 3443-3535 are essential for this binding (lane 4). Next, a series of fusion proteins with progressive NH2-terminal deletions of DCT685 (lanes 8-11 ) was examined. NH2-terminal deletions up to residue 3443 did not significantly affect the binding (lanes 9 and 10), while further NH~-terminal deletion (DCT536-685) resulted in a dramatic reduction in the binding (lane 11 ). A low affinitybinding site may exist within the residues 3536-3685, because very weak staining of A0 and/31-syntrophin was observed in lane 11. However, these deletional analyses of DCT685 from both directions collectively indicated that the essential binding site(s) for A0 and /31-syntrophin resides within the residues between 3444-3535.
~l-Syntrophin Binds to the Dystrophin C O O H Terminus as Well as [31-Syntrophin
In non-skeletal muscle tissues such as heart and brain, four tandem exons, 71-74, of the DMD gene are differentially spliced in at least l0 separate patterns to generate the distinct dystrophin isoforms (Feener et al., 1989; Bies et al., 1992) . Interestingly, the essential binding region for A0 and/31-syntrophin defined above closely corresponds to the sequence encoded by exon 73-74 (Fig. 1) . Therefore, to confirm the above results and confine the binding site(s) more precisely in relation to the exon structure of dystrophin, we constructed two additional fusion proteins, DCT444-535 and DCT444-494 (Figs. 1 and 6 ). As shown in Fig. 2 , a and b, both fusion proteins were purified without any degradation fragments and were reasonably recognized with the region-specific anti-dystrophin antibodies including PEX73 which was newly generated using DCT444-494 as an antigen. Fig. 4 a shows the results of the overlay assay with these fusion proteins. As expected, DCT444-535 strongly reacted with A0 and/31-syntrophin, which is compatible with the above results that the residues between 3444-3535 contain the essential binding site for A0 and ~l-syntrophin. Furthermore, DCT444-535 also reacted weakly but distinctly with an additional band below the broad staining on ~31-syntrophin (lane 3 in Fig. 4 a) . This band corresponds to od-syntrophin (c~-A1, syntrophin-1 or 59DAP-1), which exhibits 50% homology with/31-syntrophin but is the product of a different gene Ahn et al., 1994; Yang et al., 1994) . On the other hand, when the shorter fusion protein DCT444-494, which lacks the COOH-terminal half of the sequence contained in DCT444-535, was overlaid, A0 and ~l-syntrophin were not stained, whereas od-syntrophin was well stained.
Previously, we reported that DCT685 binds to A0 and/$1-syntrophin (t-A1), but not to od-syntrophin (oL-A1) ). This conclusion was based on the result of the overlay assay onto two dimensionally separated DAPs. In the case of DCT685, the staining on syntrophins was too strong and broad to analyze one dimensionally. We again failed to detect the staining on od-syntrophin using the fusion proteins DCT444-535 and DCT444-494 under the same conditions as the previous experiment (data not shown). This suggests that the experimental conditions using an automated electrophoresis system with a precast minigel were not suitable to detect the weak binding of dystrophin onto od-syntrophin. Therefore, in the present study, we improved the experiments by using manually cast gels (see Materials and Methods) and obtained results consistent with those obtained by onedimensional SDS-PAGE analysis (Fig. 4 b) : DCT444-535 bound to not only A0 and fll-syntrophin (arrow) but also od-syntrophin (arrowhead), whereas DCT444-494 bound only to od-syntrophin. We also confirmed that DCT685 bound to od-syntrophin as well as A0, fll-syntrophin, and fl-dystroglycan under these conditions.
Binding Sites for ~1-and fl l-Syntrophin Are Separated and Located Tandemly Around Alternative Splice-prone Exons
As shown in Fig. 5 a, P34 peptide (Tanaka et al., 1989) , which covers the non-overlap region between DCT444-535 and DCT444-494 (Figs. 1 and 6 ), bound to A0 and/~l-syntrophin but not to od-syntrophin. In addition, an excess amount of the peptide inhibited the binding of DCT444-535 to A0 and fll-syntrophin significantly, but not the binding to od-syntrophin (Fig. 5 b) . Hence, we concluded that (a) otl-and fll-syntrophin separately bind to the dystrophin COOH terminus, and (b) the binding site for od-syntrophin resides within the amino acid residues 3444-3494, while that for A0/fll-syntrophin resides within the amino acid residues 3495-3535 (Fig. 6) .
Secondary structure analysis (Chou and Fasman, 1978) predicted that the binding site for A0/~l-syntrophin forms a long a-helix flanked by the proline-rich turn structures (Fig.  6) . Interestingly, this c~-helix takes a leucine-zipper motif and is rich in acidic residues. Because/~l-syntrophin is a basic protein , the latter feature of the binding site suggested that the electrostatic interaction is important for the binding of dystrophin to Bl-syntrophin. However, the increase of the ionic strength up to 1 M NaCI scarcely affected the interactions of DCT444-535 to A0//~I-syntrophin as well as to od-syntrophin (Fig. 5 c) . This may indicate that syntrophin binding of dystrophin COOH terminus involves a predominantly hydrophobic interaction.
Other Regions May Contribute to the Dystrophin-Syntrophin Interaction
By performing competition assays between the constructed fusion proteins, we examined the syntrophin-binding affinity of each dystrophin COOH-terminal sequence. As shown in lanes I and 4 of Fig. 7, DCT444 -535, which showed substantial binding activity to syntrophin (Fig. 4 a) , could not inhibit Suzuki ¢t al. 19ystrophin-Syntrophin Interaction Figure 5 . Detailed analysis of the binding between dystrophin and two forms of syntrophin. (a) An overlay assay was performed using P34 peptide corresponding to the amino acid residues 3495-3544 of human dystrophin as a probe (lanes 2 and 3) . Detection of bound peptide was performed with the antibody, P34a. The concentrations of the overlaid peptide are 170/zg/ml (lane 2) and 500 /~g/ml (lane 3). In lanes 4 and 5, the results using DCT444-494 and DCT444-535 were shown, respectively, for comparison (the used antibody for detection was PEX73). syntrophin binding of the entire COOH-terminal sequence of dystrophin (DCT685) even at 20-fold molar excess. This indicated that the flanking region of the essential binding site for syntrophin defined above must contribute to the secure binding to syntrophin. In fact, in contrast with DCT444-535, DCT444-685, which contains the distal full sequence of COOH-terminal region, was found to compete in the syntrophin binding with DCT685 to some extent (lane 3). Therefore, the amino acid residues 3536-3685 may be involved in syntrophin binding. This idea was also supported by the result of another competition assay (lanes 5 and 6): DCT535, which lacks this distal COOH-terminal sequence down- Figure 6 . Secondary structure analysis of the essential syntrophin-binding region. The amino acid sequence (3438-3557) around the essential syntrophin-binding site is shown at the top with the predicted secondary structure (Chou and Fasman, 1978) and the exon boundaries (RJaberts et al., 1993) . In the Chou and Fasman analysis, the letters h, s, t, and c represent ct-helix,/3-sheet, turn, and coil structures, respectively. Upper case of each letter suggests the most favorable structure for the residue. Note that the ~l-syntrophin-binding site (amino acid residues 3495-3535) is rich in acidic residues (marked with asterisks) and is predicted to take a long c~-helix structure (underlined). This c~-helix contains a stretch of four leucines in the heptad repeat (underlined), suggesting that it takes leucine-zipper motif. These leucine residues are well conserved even in utrophin (Tinsley et al., 1992) . This leucine-zipper motif precedes the other one which has been suggested to locate within the amino acid residues 3558-3594 (Wagner et al., 1993) . One of the potential phosphorylation site by p34 ~c2 is boxed (Milner et al., 1993) stream from residue 3536, inhibited syntrophin binding of DCT685 greatly but incompletely, although it completely abolished/3-dystroglycan binding of DCT685. These results are consistent with the observation in Fig. 3 which suggested that this sequence may contain another low affinity-binding site for A0//31-syntrophin.
On the other hand, the GPC-binding region may also affect the syntrophin binding of dystrophin, because the inhibition of DCT444-685 against A0//31-syntrophin binding of DCT685 was rather incomplete (lane 3). This was the case when DCT264-685 was used as a competitor in place of DCT444-685 0ane 2). These results excluded the possibility that the steric hindrance arising from fused GST was the cause of the incompleteness of the inhibition, and suggested that the lack or disruption of the GPC-binding region may weaken the binding affinity of dystrophin to A0//31-syntrophin.
D i s c u s s i o n
In the present work, by using the overlay assay method, we showed that two forms of syntrophin, od-and/31-syntrophin (Adams et al., 1993; Alan et al., 1994; Yang et al., 1994) , which are the membrane extrinsic proteins (Froehner, 1984; Ervasti and Campbell, 1991) , directly bind to dystrophin at the vicinity of the GPC-binding site (Fig. 1) . Their essential binding sites are confined to the region between amino acid residues 3444-3535. In addition, a low afffinity-binding site is also suggested to exist at the more COOH-terminal region.
In Fig. 8 , we propose a new idea on the domain organization of the dystrophin COOH-terminal region from the viewpoint of protein-protein interactions: the cysteine-rich domain and the first half of the COOH-terminal domain are together renamed "the dystroglycan-binding domain" (amino acid residues 3080-3408), since this region binds to the dystroglycan complex as a single functional unit . It should be noted that this domain is a genuine "cysteine-rich region" in which the well-conserved cysteine residues are concentrated (see Figs. 1 and 8 ). As we demonstrated previously, these cysteine residues are important for the binding to/3-dystroglycan .
On the other hand, since the last half of the COOHterminal domain, which is not essential for GPC binding , forms a domain to interact with syntrophins, we propose to call this region "the syntrophinbinding domain" (amino acid residues 3409-3685). This domain contains two leucine-zipper motifs possibly important (Koenig et al., 1988; Hoffman and Kunkel, 1989 ) and a new model (bottom) based on the results of DAPbinding activities and the limited digestion of dystrophin Yoshida et al., 1992; ; and the present work) are illustrated. The difference between the two lies at the COOH-terminal end of dystrophin, where the cysteine-rich domain and the first half of the COOH-terminal domain in the original model are combined to form "the dystroglycan-binding domain" (amino acid residues 3080-3408) in the new model . The remaining distal part of the dystrophin COOH terminus (amino acid residues 3409-3685), which corresponds to the last half of the COOH-terminal domain in the original model, is suggested to interact with syntrophin, thus designated as "syntrophin-binding domain:' A0, a minor dystrophin-associated protein with a molecular mass of 97 kD which is immunochemically related to syntrophin, also binds to this domain. The vertical lines represent the positions of the cysteine residues. Alternative splicing patterns so far reported are also indicated (Feener et al., 1989; Bies et al., 1992) .
for protein-protein interactions (one of which corresponds to the amino acid residues 3498-3533 [first suggested in this paper ; see Fig. 6 ] and the other corresponds to the residues 3558-3594 [Wagner et al., 1993] ). We identified here that the proximal motif coincides with the essential binding site for/31-syntrophin. The syntrophin-binding domain also contains two predicted phosphorylation sites by p34 cdc~ (Milner et al., 1993) , one of which is located within the intermediate region of the two leucine zipper motifs (Fig. 6) . Together with the fact that this domain contains the alternative spliceprone region ( Fig. 8; Feener et al., 1989; Bies et al., 1992) , these results imply that this is the locus of various regulatory activities for dystrophin function. Because this domain is very susceptible to proteinase digestion, it is considered not to have a tightly packed structure Yoshida et al., 1992) .
It may be of biological importance that the essential syntrophin-binding site defined here (amino acid residues 3444-3535) coincides with the region which is subjected to the tissue-type specific alternative splicing (Fenner et al., 1989; Bies et al., 1992) . This is consistent with the results of Ahn et al. (1994) that the sequence encoded by exon 74 is the site for/31-syntrophin binding (the accompanied paper). This means that the function of syntrophin is tightly linked to the isoform-specific function of dystrophin, and some dystrophin isoforms may function without interacting with syntrophins. Most tissues express multiple isoforms of dystrophin, suggesting that multiple functions of dystrophin are required even in a single cell (Bies et al., 1992) . As for the isoforms lacking the region encoded by exon 74, they are predominantly detected in brain, heart and smooth muscles, but very rarely in skeletal muscles (Bies et al., 1992) . These results indicate that the interaction with syntrophins is indispensable for skeletal muscle dystrophin. This represents a keen coincidence with the components of the sarcoglycan complex (Adhalin, A3b and 35DAG) which are solely expressed in the striated muscles (Roberds et al., 1993; Mizuno et al., 1993; Yamamoto et al., 1994) and the loss or great reduction of which is commonly observed in both SCARMD and DMD (Matsumura et al., 1992; Mizuno et al., 1994; Yamanouchi et al., 1994) . This might also suggest that syntrophins work cooperatively with sarcoglycan complex in the modulation of the symptoms. Indeed, the binding site for od-syntrophin, which is predominantly expressed in skeletal muscle (Adams et al., 1993; Yang et al., 1994) , precisely matches amino acid residues 3444-3485, the deletion of which causes a phenotype showing severe muscle wasting . In this sense, it is a challenging subject to clarify whether the direct interaction between syntrophin and the components of GPC exists or not.
Recent works on cDNA cloning established the heterogeneity of the mammalian syntrophin (Adams et al., 1993; Ahn et al., 1994; Yang et al., 1994) : there are three forms of syntrophin (cd-,/31-, and/~2-syntrophin), which originate from different genes (their nomenclature was given in Peters et al. [1994] ). In the present work, we have shown that or-and/31-syntrophin bind to very close but discrete sites on dystrophin. Considering the overall homology (50%) between the two forms of syntrophin (Alan et al., 1994) , it is interesting that they bind to completely different amino acid sequences on the dystrophin molecule (Fig. 6) : the binding site for cdsyntrophin (amino acid residues 3444-3494) did not show affinity to/31-syntrophin, and vice versa (Figs. 4 and 5) . This finding leads to the suggestion that the amino acid sequence of each syntrophin involved in the interaction with dystrophin should be different from the other. It is tempting to consider that the functional diversity of syntrophins is mostly localized in their respective interaction regions with dystrophin. One might consider the possibility that the bindings of ed-and/31-syntrophins are mutually exclusive, because the binding loci for both syntrophins are too close (Fig. 6) . However, this possibility may be excluded by our preliminary observation that al-and /31-syntrophin associate with each other (Yoshida and Ozawa, 1990) . Therefore, it is likely that or-and/31-syntrophin bind to a single dystrophin molecule in the fixed arrangement simultaneously.
Finally, we observed that A0 binds to dystrophin at the same region as/31-syntrophin. This protein, with a molecular mass of 94 kD, is a minor component of dystrophin-DAP complex purified from sarcolemma. Because At) shows similar biochemical nature to syntrophin and cross-reacts with an anti-syntrophin antibody , A0 may also be a member of the syntrophin family.
